Last edition
News about
Novo Nordisk's Zenagamtide Delivers Up to 14.6 Percent Weight Loss in Type 2 Diabetes
Novo Nordisk’s investigational once-weekly therapy zenagamtide demonstrated significant A1C reductions and up to 14.6 percent weight loss in adults with Type 2 Diabetes in a phase 2 trial presented at ADA 2026. The strong results support advancement of zenagamtide into phase 3 clinical development.
Pfizer's Berobenatide Shows Strong Phase 2b Results with Monthly Dosing
Pfizer’s GLP-1 receptor agonist berobenatide demonstrated robust efficacy and favorable tolerability in a Phase 2b trial, supporting once-monthly dosing.
Akums Secures European CEP Approval for Cefpodoxime Proxetil API
Akums Drugs and Pharmaceuticals has received a Certificate of Suitability from the EDQM for its Cefpodoxime Proxetil API, reinforcing the company’s commitment to global quality compliance and enhancing its position as a trusted manufacturing partner for regulated international markets.
GVRP and Steps Biosciences Launch Advanced Formulations Research Centre in Bengaluru
GVRP and Steps Biosciences have inaugurated the GVRP StepsBio Research Centre (GSRC) at Bengaluru’s Lifescapes life sciences cluster, strengthening India’s pharmaceutical innovation ecosystem with advanced facilities for complex formulations, sterile injectables, analytical testing and AI-enabled drug development.
WuXi Biologics Completes Topping-Out of Singapore Drug Product Facility
WuXi Biologics has completed the modular topping-out of its Singapore CRDMO hub drug product facility, a key manufacturing site designed to meet stringent standards. Once operational, the facility is expected to produce approximately 100 million pre-filled syringes and vials annually.
DST-TDB Supports Bioneemtec for Green Pharma Manufacturing Commercialisation
The Department of Science and Technology (DST) is supporting Bioneemtec India in the commercialisation of green chemistry-based pharmaceutical manufacturing technologies, aiming to strengthen indigenous API production and advance next-generation therapeutics.
Teva Pharma Launches AHZANTIVE Biosimilar to Eylea in Europe
Teva has launched AHZANTIVE (aflibercept), an EMA-approved biosimilar to Eylea, across Europe. Demonstrating comparable efficacy, safety, and immunogenicity to the reference product, the launch expands Teva’s biosimilars and ophthalmology portfolio while supporting its long-term Pivot to Growth strategy.
Owkin and Sanofi Partner to Develop AI Agents for Drug Discovery
Owkin and Sanofi have expanded their multi-year K Pro collaboration to develop AI agents that enhance drug discovery and development. By integrating agentic AI systems into research workflows, the partnership aims to unlock the full value of data, improve decision-making, and accelerate the development of innovative therapies.
IntraBio Submits EMA Variation Application for AQNEURSA in Ataxia-Telangiectasia
IntraBio has submitted a variation application to the European Medicines Agency (EMA) for AQNEURSA as a treatment for Ataxia-Telangiectasia. If approved, it would become the first authorised therapy for this disorder in the European Economic Area.
Lupin Receives US FDA Approval for Interchangeable Biosimilar Ranibizumab, Ranluspec
Lupin has secured US FDA approval for Ranluspec (ranibizumab-hkdz), an interchangeable biosimilar to Lucentis, expanding its biosimilars portfolio and broadening access to treatments for retinal and vision-related disorders.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy